We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
To make remdesivir available to COVID-19 patients in low-income nations, Gilead Sciences has signed non-exclusive licensing agreements with five generic drugmakers to allow them to manufacture and sell the antiviral. Read More
About 28 million doses of hydroxychloroquine were distributed from the Strategic National Stockpile last month and states are wondering what to do with their excess supply since studies have cast doubt on the drug’s benefit as a COVID-19 treatment. Read More
Famotidine, a heartburn medicine better known as Pepcid, has been added to the FDA’s drug shortage list shortly after it became known that the drug is being tested as a COVID-19 treatment. Read More
Two lawmakers are pressing Jaguar Health to reverse the three-fold price hike on its diarrhea drug Mytesi (crofelemer) that has been considered as a possible COVID-19 treatment. Read More
HHS and FEMA will control the distribution of Gilead’s remdesivir as a COVID-19 treatment as a condition of its Emergency Use Authorization (EUA) by the FDA. Read More
Moderna has signed a 10-year agreement with Swiss manufacturer Lonza to manufacture its COVID-19 vaccine candidate and other future products. Read More